Home / Search / Epilepsy

Epilepsy

Best controlled of the major neurological disorders, roughly 70% of patients achieve seizure control with existing therapies. Drug-resistant epilepsy (the remaining 30%) is the core unmet research need.

Search Epilepsy evidence →
540
Papers (5yr)
6
Active trials
2
Tracked biomarkers
1
Related diseases
Research signals

Next-generation high-affinity SV2A ligands completed Phase I with 3x potency improvement. SV2A pathway overlap with ALS synaptic dysfunction models is an emerging cross-disease signal. View full research signals ->

Tracked biomarkers
EEG biomarkersStrong evidence

Interictal epileptiform discharges remain the primary diagnostic and research biomarker.

SV2A PETModerate evidence

Synaptic density imaging. Used in next-generation SV2A modulator trials.

Active clinical trials
NCT IDDrugPhaseStatusSponsor
NCT05512104High-affinity SV2A ligandPhase IIRecruitingAcademic consortium

View all ALS trials in platform →

Related diseases — shared mechanisms

Phase 1 primary cohort + monitored diseases

ALS
Shared: SV2A synaptic pathway overlap
Research and educational use only. Information does not constitute medical advice, diagnosis, or treatment recommendations. Verify with primary literature. AI disclaimer →